Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients

Inclusion Criteria:

* At least one measurable lesion (the length of spiral CT scan (\> 10mm) meets the requirements of RESCIST 1.1) is found in patients with HCC confirmed by histopathology or cytology or who meet the clinical diagnostic criteria.
* ≥ 18 and ≤ 75 years of age
* ECOG performance status of 0-1
* No prior treatment for advanced disease (adjuvant therapy allowed)
* Life expectancy of at least 3 months
* The main organs are functioning normally.
* Neutrophils count =/\> 1.5 x 109/L, platelets count =/\> 100 x 109/L, HGB =/\> 90 g/L
* total bilirubin =/\< 1.5 x UNL • SGOT and SGPT =/\< 2.5 x UNL (=/\< 5 x UNL in patients with liver metastases)
* Creatinine =/\< 1.5 x UNL
* Patients who are molecularly diagnosed as having RAS and BRAF wild-type mCRC are Histologically/cytologically confirmed as advanced, colorectal cancer.
* Subjects volunteered to join the study, signed informed consent, good compliance, with follow-up.

Exclusion Criteria:

* Pregnant or lactating women.
* Active or untreated CNS metastases as determined by CT or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments.
* Patients with hypertension who could not be well controlled by antihypertensive drugs (systolic blood pressure \> 150 mmHg, diastolic blood pressure \> 100 mmHg), patients with myocardial infarction, arrhythmias with poor control (including QTC interval \> 450 ms) and cardiac insufficiency of grade II according to NYHA standard.
* with bleeding tendency or undergoing thrombolysis or anticoagulation therapy.
* serious uncontrolled intercurrence infection.
* Proteinuria ≥ 2+ (1.0g/24hr).
* Have evidence or a history of bleeding tendency within two months of the enrollment, regardless of seriousness.
* Within 6 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc.
* Have a history of mental illness or psychotropic drug abuse.
* Patients with a history of immunodeficiency(or autoimmue disease), or other acquired congenital immunodeficiency diseases, or a history of organ transplantation and hematopoietic stem cell transplantation.
* Patients who are allergic to components of Capecitabine preparations, Oxaliplatin injection and anlotinib preparations.
* According to the researchers' judgment, there are serious concomitant diseases that endanger patient safety or prevent patients from completing the study.
* Patients who have received prior systemic chemotherapy, targeted therapy, immunity therapy or any medication within 30 days.